A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Study Status
Open to Enrollment
Study Description
The purpose of this study is to determine the anti-tumor activity of the combination of apricoxib plus either docetaxel or pemtrexed, compared with placebo (an inactive drug that looks like the study drug) plus either docetaxel or pemetrexed in patient with Stage IIIB or Stage IV non-small cell lung cancer.
Disease Status and/or Stage
Stage IIIB/IV or Recurrent, Unresectable Non-Small Cell Lung Cancer
Sponsor
Tragara Pharmaceuticals
Key Eligibility
- Men and women age 18 and older
- Stage IIIB or IV non-small cell lung cancer
- Additonal eligibility criteria discussed when you contact the study team
Principal Investigator
Contact
- Gina Mileo
- 212-746-5430
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]
